ARID3B directly regulates ovarian cancer promoting genes

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Bobbs, Alexander ^a,b   Gellerman, Katrina ^b,c   Hallas, William Morgan ^b,c   Joseph, Stancy ^a,b   Yang, Chao ^b,c   Kurkewich, Jeffrey ^b,c   Cowden Dahl, Karen D ^a,b,c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Harper Cancer Institute   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; FZD5 PROTEIN; MESSENGER RNA; NOTCH RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN; WNT PROTEIN; WNT5A PROTEIN; ARID3B PROTEIN, HUMAN; DNA BINDING PROTEIN; FRIZZLED PROTEIN; FZD5 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARID3B GENE; ARTICLE; CANCER CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EGF GENE; EXTRACELLULAR MATRIX; FEMALE; FZD5 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC SCREENING; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NOTCH GENE; OVARY CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR PROMOTION; ALGORITHM; ANIMAL; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; OVARY TUMOR; TUMOR CELL LINE;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; FRIZZLED RECEPTORS; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VITRONECTIN;

EID: 84938633286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131961     Document Type: Article

References (50)

1. American Cancer Society (2014) Cancer Facts and Figures.
2. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009; 11(11):1208-15. Epub 2009/11/03. PMID: 19881956; PubMed Central PMCID: PMC2767222.
3. Roy L, Samyesudhas SJ, Carrasco M, Li J, Dahl R, Cowden Dahl KD. ARID3B accererates ovarian cancer progression in vivo by inducing multiple tumor promoting pathways. Oncotarget. 2014;In Press.
4. Gregory SL, Kortschak RD, Kalionis B, Saint R. Characterization of the dead ringer gene identifies a novel, highly conserved family of sequence-specific DNA-binding proteins. Mol Cell Biol. 1996; 16 (3):792-9. Epub 1996/03/01. PMID: 8622680; PubMed Central PMCID: PMC231059.
5. Herrscher RF, Kaplan MH, Lelsz DL, Das C, Scheuermann R, Tucker PW. The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. Genes Dev. 1995; 9(24):3067-82. Epub 1995/12/15. PMID: 8543152.
6. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP, et al. ENCODE whole-genome data in the UCSC genome browser (2011 update). Nucleic Acids Res. 2011; 39(Database issue):D871-5. Epub 2010/11/03. doi: 10.1093/nar/gkq1017gkq1017 [pii]. PMID: 21037257; PubMed Central PMCID: PMC3013645.
7. Rhee C, Lee BK, Beck S, Anjum A, Cook KR, Popowski M, et al. Arid3a is essential to execution of the first cell fate decision via direct embryonic and extraembryonic transcriptional regulation. Genes Dev. 2014; 28(20):2219-32. Epub 2014/10/17. doi: 10.1101/gad.247163.114 28/20/2219 [pii]. PMID: 25319825; PubMed Central PMCID: PMC4201284.
8. Numata S, Claudio PP, Dean C, Giordano A, Croce CM. Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product. Cancer Res. 1999; 59(15):3741-7. Epub 1999/08/14. PMID: 10446990.
9. Chien CS, Wang ML, Chu PY, Chang YL, Liu WH, Yu CC, et al. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State. Cancer Res. 2015. Epub 2015/04/11. doi: canres.2215.2014 [pii] 0008-5472.CAN-14-2215 [pii] doi: 10.1158/ 0008-5472.CAN-14-2215 PMID: 25858147.
10. Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002; 13 (3):95-106. Epub 2002/04/18. PMID: 11959810.
11. Casanova JC, Uribe V, Badia-Careaga C, Giovinazzo G, Torres M, Sanz-Ezquerro JJ. Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements. Development. 2011; 138(6):1195-205. Epub 2011/02/11. doi: 10.1242/dev.057570 dev.057570 [pii]. PMID: 21307092.
12. Takebe A, Era T, Okada M, Martin Jakt L, Kuroda Y, Nishikawa S. Microarray analysis of PDGFR alpha + populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. Dev Biol. 2006; 293(1):25-37. Epub 2006/03/15. doi: S0012-1606(05)00889-4 [pii] doi: 10.1016/j. ydbio.2005.12.016 PMID: 16530748.
13. Webb CF, Bryant J, Popowski M, Allred L, Kim D, Harriss J, et al. The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development. Mol Cell Biol. 2011; 31 (5):1041-53. Epub 2011/01/05. doi: 10.1128/MCB.01448-10 MCB.01448-10 [pii]. PMID: 21199920; PubMed Central PMCID: PMC3067827.
14. Kobayashi K, Era T, Takebe A, Jakt LM, Nishikawa S. ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer Res. 2006; 66(17):8331-6. Epub 2006/09/05. doi: 66/17/8331 [pii] doi: 10.1158/0008-5472.CAN-06-0756 PMID: 16951138.
15. Kobayashi K, Jakt LM, Nishikawa SI. Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn. Oncogene. 2013; 32(21):2640-8. Epub 2012/07/04. doi: 10.1038/onc.2012.285 onc2012285 [pii]. PMID: 22751132; PubMed Central PMCID: PMC3664305.
16. Arend RC, Londono-Joshi AI, Straughn JM Jr., Buchsbaum DJ. The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecol Oncol. 2013; 131(3):772-9. Epub 2013/10/16. doi: 10.1016/j.ygyno. 2013.09.034 S0090-8258(13)01252-3 [pii]. PMID: 24125749.
17. Arend RC, Londono-Joshi AI, Samant RS, Li Y, Conner M, Hidalgo B, et al. Inhibition of Wnt/beta-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecol Oncol. 2014; 134(1):112-20. Epub 2014/04/17. doi: 10.1016/j.ygyno.2014.04.005 S0090-8258(14)00862-2 [pii]. PMID: 24736023.
18. Peng C, Zhang X, Yu H, Wu D, Zheng J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int J Gynecol Cancer. 2011; 21(2):280-8. Epub 2011/ 01/29. doi: 10.1097/IGC.0b013e31820aaadb 00009577-201102000-00014 [pii]. PMID: 21270611.
19. Ford CE, Punnia-Moorthy G, Henry CE, Llamosas E, Nixdorf S, Olivier J, et al. The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Gynecol Oncol. 2014. Epub 2014/06/14. doi: S0090-8258(14)01029-4 [pii] doi: 10. 1016/j.ygyno.2014.06.004 PMID: 24924122.
20. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA 2nd, McAsey ME, et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway. Mol Cancer Res. 2012; 10(3):469-82. Epub 2012/01/11. doi: 10.1158/1541-7786.MCR-11-0177 1541-7786.MCR-11-0177 [pii]. PMID: 22232518; PubMed Central PMCID: PMC3307825.
21. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981; 68(5):1331-7. Epub 1981/11/01. PMID: 7028788; PubMed Central PMCID: PMC370929.
22. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993; 53(4):891-8. Epub 1993/02/15. PMID: 8094034.
23. Joseph S, Deneke VE, Cowden Dahl KD. ARID3B induces tumor necrosis factor alpha mediated apoptosis while a novel ARID3B splice form does not induce cell death. PLoS One. 2012; 7(7):e42159. Epub 2012/08/04. doi: 10.1371/journal.pone.0042159 PONE-D-12-10269 [pii]. PMID: 22860069; PubMed Central PMCID: PMC3409141.
24. Fogh J. Human Tumor Cells in vitro. New York: Plenum Press; 1975.
25. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983; 43(11):5379-89. Epub 1983/11/01. PMID: 6604576.
26. Karlan BY, Jones J, Slamon DJ, Lagasse LD. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells. Gynecol Oncol. 1994; 53(1):70-7. Epub 1994/04/01. doi: S0090825884710900 [pii]. PMID: 7909787.
27. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977; 36(1):59-74. Epub 1977/07/01. PMID: 886304.
28. Choi JH, Choi KC, Auersperg N, Leung PC. Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab. 2004; 89(11):5508-16. Epub 2004/11/09. doi: 89/11/5508 [pii] doi: 10.1210/jc.2004-0044 PMID: 15531506.
29. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol. 2005; 12(6):882-93. Epub 2005/08/20. doi: 10.1089/cmb.2005.12.882 PMID: 16108723.
30. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-21. Epub 2001/04/20. doi: 10.1073/pnas. 091062498 PMID: 11309499; PubMed Central PMCID: PMC33173.
31. Tamimi Y, Lines M, Coca-Prados M, Walter MA. Identification of target genes regulated by FOXC1 using nickel agarose-based chromatin enrichment. Invest Ophthalmol Vis Sci. 2004; 45(11):3904-13. Epub 2004/10/27. doi: 45/11/3904 [pii] doi: 10.1167/iovs.04-0628 PMID: 15505035.
32. Bailey TL, Elkan C. Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol. 1994; 2:28-36. Epub 1994/01/01. PMID: 7584402.
33. Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009; 37(Web Server issue):W202-8. Epub 2009/05/22. doi: 10.1093/nar/gkp335 gkp335 [pii]. PMID: 19458158; PubMed Central PMCID: PMC2703892.
34. Halperin Y, Linhart C, Ulitsky I, Shamir R. Allegro: analyzing expression and sequence in concert to discover regulatory programs. Nucleic Acids Res. 2009; 37(5):1566-79. Epub 2009/01/20. doi: 10.1093/ nar/gkn1064 gkn1064 [pii]. PMID: 19151090; PubMed Central PMCID: PMC2655690.
35. Linhart C, Halperin Y, Shamir R. Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res. 2008; 18(7):1180-9. Epub 2008/04/ 16. doi: 10.1101/gr.076117.108 gr.076117.108 [pii]. PMID: 18411406; PubMed Central PMCID: PMC2493407.
36. Carey MF, Peterson CL, Smale ST. Chromatin immunoprecipitation (ChIP). Cold Spring Harb Protoc. 2009; 2009(9):pdb prot5279. Epub 2010/02/12. doi: 10.1101/pdb.prot5279 2009/9/pdb.prot5279 [pii]. PMID: 20147264.
37. Samyesudhas SJ, Roy L, Cowden Dahl KD. Differential expression of ARID3B in normal adult tissue and carcinomas. Gene. 2014; 543(1):174-80. Epub 2014/04/08. doi: 10.1016/j.gene.2014.04.007 S0378-1119(14)00407-7 [pii]. PMID: 24704276.
38. Kim D, Probst L, Das C, Tucker PW. REKLES is an ARID3-restricted multifunctional domain. J Biol Chem. 2007; 282(21):15768-77. Epub 2007/04/03. doi: M700397200 [pii] doi: 10.1074/jbc. M700397200 PMID: 17400556.
39. Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 2014; 35(5):4389-99. Epub 2014/01/07. doi: 10.1007/s13277-013-1578-1 PMID: 24390615.
40. Qiu JJ, Guo JJ, Lv TJ, Jin HY, Ding JX, Feng WW, et al. Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer. Tumour Biol. 2013; 34(5):2971-5. Epub 2013/05/ 29. doi: 10.1007/s13277-013-0860-6 PMID: 23712606.
41. Ricken A, Lochhead P, Kontogiannea M, Farookhi R. Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt-2b, and frizzled-4 mRNAs. Endocrinology. 2002; 143 (7):2741-9. Epub 2002/06/20. doi: 10.1210/endo.143.7.8908 PMID: 12072409.
42. Barbolina MV, Burkhalter RJ, Stack MS. Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J. 2011; 437(1):1-12. Epub 2011/06/15. doi: 10.1042/ BJ20110112 BJ20110112 [pii]. PMID: 21668411; PubMed Central PMCID: PMC3133882.
43. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. Epub 2006/10/28. doi: 1476-4598-5-50 [pii] doi: 10.1186/1476-4598-5-50 PMID: 17067392; PubMed Central PMCID: PMC1635730.
44. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993; 53(16):3830-8. Epub 1993/08/15. PMID: 8339295.
45. Berns EM, Klijn JG, Henzen-Logmans SC, Rodenburg CJ, van der Burg ME, Foekens JA. Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer. 1992; 52(2):218-24. Epub 1992/09/09. PMID: 1325950.
46. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer. 1996; 73 (3):301-6. Epub 1996/02/01. PMID: 8562334; PubMed Central PMCID: PMC2074444.
47. Niikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 1997; 16 (1):60-8. Epub 1997/01/01. PMID: 8986534.
48. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G, Greggi S, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol. 1992; 10(4):529-35. Epub 1992/04/01. PMID: 1548517.
49. Stewart CJ, Owens OJ, Richmond JA, McNicol AM. Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors. Int J Gynecol Pathol. 1992; 11(4):266-72. Epub 1992/10/01. PMID: 1399232.
50. van der Burg ME, Henzen-Logmans SC, Foekens JA, Berns EM, Rodenburg CJ, van Putten WL, et al. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer. 1993; 29A (14):1951-7. Epub 1993/01/01. PMID: 8280488.